Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Novartis AG (ADR) (NVS) Agrees To $50 Million Deal With Conatus Pharmaceuticals Inc (CNAT)

Novartis AG (ADR) (NYSE:NVS) and Conatus Pharmaceuticals Inc (NASDAQ:CNAT) will jointly develop Conatus drug emricasan. This has resulted from the duo’s agreement under which the small U.S. company will receive $50 million upfront before further payments can follow.

The exclusive collaboration and license agreement will facilitate effective development of a new experimental first-in-class oral treatment for non-alcoholic steatohepatitis (NASH) with advanced fibrosis and cirrhosis.

merger, businessman, greeting, handshake, hands, business, concept, handclasp, success, friendship, symbol, partnership, tone, cooperation, people, agree, welcome,

Kritchanut/Shutterstock.com

The partnership comes at a time when several drugmakers the likes of liver specialists such as Intercept Pharmaceuticals and Genfit are pursuing treatments for NASH. It is expected to help in the expansion of treatment options for chronic, progressive fatty liver condition, which involves inflammation and scarring. With the enormous patient population, this is likely to be a potential solution to a huge unmet need.

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) Will Conduct Multiple Phase 2b Clinical Trials

One of the conditions of the collaboration is that Conatus Pharmaceuticals Inc (NASDAQ:CNAT) will conduct multiple Phase 2b clinical trials with emricasan in NASH. Thereafter, the Swiss drugmaker will conduct Phase III studies of the drug before its development. This will be done in combination with the experimental treatment for chronic liver disease commonly known as an FXR agonist.

According to Steven Mento, Conatus Chief Executive, the resources are in place. He quotes, “For Conatus, the near-term infusion of capital and Phase IIb cost-sharing allows us to fund ongoing operations through 2019.”

Estimates Indicate That NASH Affects 3% – 5% Of The U.S. Population

Records reveal that NASH is headed to becoming the lead cause of liver transplants in the United States by 2020. Something must be done. However, any cause of alarm may be tamed by the presence of big Biomed NASH players such as Gilead Sciences, Inc. (NASDAQ:GILD) and Allergan plc Ordinary Shares (NYSE:AGN) who are seeking entry into the NASH development field as well.

Follow Novartis A G (NYSE:NVS)
Trade (NYSE:NVS) Now!

On the other hand, Intercept, which does not trade on U.S. exchanges, recently won tentative European approval of a NASH drug for another liver disease. Meanwhile, Novartis AG (ADR) (NYSE:NVS) closed at $71.63, a decline of $0.15 or 0.21%.

Follow Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)
Trade (NASDAQ:CNAT) Now!

Note: This article is written by Adam Russell and originally published at Market Exclusive.